nature portfolio

Corresponding author(s): COMMSCHEM-24-0250

Last updated by author(s): May 23, 2024

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our Editorial Policies and the Editorial Policy Checklist.

Statistics

For	all st	atistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.			
n/a	Cor	Confirmed			
	\boxtimes	The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement			
	\square	A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly			
		The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.			
\boxtimes		A description of all covariates tested			
\boxtimes		A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons			
		A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)			
		For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted Give P values as exact values whenever suitable.			
\boxtimes		For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings			
\boxtimes		For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes			
	\square	Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated			
		Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.			
	_				

Software and code

Policy information about <u>availability of computer code</u>				
Data collection	Mass spectrometry was performed on Aglient 7250 GC/Q-TOF (USA), 1H and 13C NMR were recorded on a Bruker Avance 400 spectrometer, Emission spectra and lifetime measurements were performed on a PTI TimeMaster C720 Spectrometer			
Data analysis	Data was analyzed with Graphpad Prism 10, All NMR data were acquired and processed using standard Bruker software			

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

Data

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable: - Accession codes, unique identifiers, or web links for publicly available datasets

- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

The authors declare that the data supporting the findings of this study are available within the paper and its Supplementary Information files.

Human research participants

Policy information about studies involving human research participants and Sex and Gender in Research.

Reporting on sex and gender	Use the terms sex (biological attribute) and gender (shaped by social and cultural circumstances) carefully in order to avoid confusing both terms. Indicate if findings apply to only one sex or gender; describe whether sex and gender were considered in study design whether sex and/or gender was determined based on self-reporting or assigned and methods used. Provide in the source data disaggregated sex and gender data where this information has been collected, and consent has been obtained for sharing of individual-level data; provide overall numbers in this Reporting Summary. Please state if this information has not been collected. Report sex- and gender-based analyses where performed, justify reasons for lack of sex- and gender-based analysis.
Population characteristics	Describe the covariate-relevant population characteristics of the human research participants (e.g. age, genotypic information, past and current diagnosis and treatment categories). If you filled out the behavioural & social sciences study design questions and have nothing to add here, write "See above."
Recruitment	Describe how participants were recruited. Outline any potential self-selection bias or other biases that may be present and how these are likely to impact results.
Ethics oversight	Identify the organization(s) that approved the study protocol.

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

Life sciences Behavioural & social sciences Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see <u>nature.com/documents/nr-reporting-summary-flat.pdf</u>

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	All replicates samples were examined and we did not sample only part of them.
Data exclusions	No data was excluded
Replication	All experimental were carried out at least three times on different experimental days
Randomization	All samples were allocated into experimental group in random
Blinding	The investigators were not blinded. Blinding is not technically or practically feasible for the experiments in this work

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems

N /	_	<u>ь</u> I	_	_	-1	
IVI	e	Tľ	n	О	d	S
	_			-		_



Eukaryotic cell lines

Policy information about <u>cell lines and Sex and Gender in Research</u>					
Cell line source(s)	THLE-2 (Meisen CTCC, CTCC-004-0030) is an epithelial cell that was isolated from the left lobe of a donor. Hep G2 (Meisen CTCC, CTCC-003-0085) is a cell line exhibiting epithelial-like morphology that was isolated from a hepatocellular carcinoma of a 15-year-old, White, male youth with liver cancer.				
Authentication	Authentication by STR analysis. see Source Data file for details.				
Mycoplasma contamination	The cell lines were not tested for Mycoplasma contamination				
Commonly misidentified lines (See <u>ICLAC</u> register)	Name any commonly misidentified cell lines used in the study and provide a rationale for their use.				